Across TCGA pan-cancer cohorts, IHH mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IHH data layer compared with 26 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IHH mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IHH expression acts as an unfavorable survival marker.
UCEC are the cancer types where IHH mass-spec protein most reproducibly stratifies survival.